Translate Bio (Nasdaq: TBIO), the messenger RNA (mRNA) company, was trading up to 76% higher in pre-market activity on Tuesday.
The US biotech had just announced that it was expanding its existing 2018 collaboration and license agreement with French pharma major Sanofi (Euronext: SAN) to develop mRNA vaccines across all infectious disease areas.
Translate Bio will receive $425 million in an upfront payment and common stock equity investment, and overall is eligible to receive up to $1.9 billion of potential milestone payments, as well as tiered royalties on worldwide sales of developed vaccines.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze